Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure

Area of Science:

• Cardiology
• Biomarkers
• Heart Failure Management

Background:

• Limited data exists on the prognostic value of brain natriuretic peptide (BNP) in mildly symptomatic heart failure (HF) patients undergoing cardiac resynchronization therapy with a defibrillator (CRT-D).
• Assessing BNP may offer crucial insights into treatment response and patient outcomes in this population.

Purpose of the Study:

• To investigate the prognostic implications of baseline and 1-year brain natriuretic peptide (BNP) levels in patients with mildly symptomatic heart failure (HF) treated with cardiac resynchronization therapy with a defibrillator (CRT-D).
• To evaluate the association between BNP levels and the risk of HF events or death.
• To compare BNP changes and their prognostic significance between CRT-D and implantable cardioverter defibrillator-only (ICD-only) therapy.

Main Methods:

• A cohort of 1197 patients with baseline BNP data from the Multicenter Automated Defibrillator Implantation Trial-CRT (MADIT-CRT) was analyzed.
• Baseline and 1-year BNP levels were dichotomized at the upper tertile (120 pg/mL).
• The risk of HF or death was assessed in relation to BNP levels and therapy allocation (CRT-D vs. ICD-only).

Main Results:

• Elevated baseline BNP significantly increased the risk of HF or death by 68% in CRT-D patients and 58% in ICD-only patients.
• CRT-D patients showed a significant 26% reduction in BNP at 1 year, unlike ICD-only patients (8% increase; P=0.005).
• Reduced or low 1-year BNP levels in CRT-D patients were associated with a significantly lower risk of HF or death and higher echocardiographic response.

Conclusions:

• Baseline and follow-up BNP assessments provide significant prognostic information for mildly symptomatic HF patients receiving CRT.
• Monitoring BNP levels can help identify patients at higher risk and guide therapeutic decisions in HF management.